SAM #DARPA-SN-26-61

DARPA RFI: Hemorrhage Countermeasure Evaluation and Commercialization Support

DARPA's Biological Technologies Office is seeking information from organizations with capabilities to support the evaluation and commercialization of hemorrhage countermeasures. - Request for Information (RFI) focused on independent verification and validation, clinical trial support, and commercialization assistance - No specific products, OEMs, or part numbers are listed; the focus is on service capabilities - Respondents should be able to provide third-party safety and efficacy assessments for hemorrhage countermeasures - Support for transitioning products from research and development to civilian and government markets is required - Comprehensive responses addressing all task domains (verification, validation, clinical trials, commercialization) are preferred - No purchase quantities or contract values specified - Place of performance and contracting office is DARPA headquarters in Arlington, VA

Description

The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency(DARPA) seeks input from industry and academia regarding capabilities for providing independent verification and validation, clinical trial, and commercialization support for hemorrhage countermeasures. This Request for Information (RFI) is a preliminary step to identify potential partners capable of providing third-party assessments of safety and efficacy of potential hemorrhage countermeasures and assisting in development strategies to ensure said products transition from the laboratory to civilian and government markets after research, development, testing, and evaluation (RDT&E) efforts have ended. DARPA is particularly interested in respondents who can address all the above task domains to allow one provider to have comprehensive knowledge about the data for efficiency and to tailor commercialization and regulatory strategies.

View original listing